Citi Boosts Eli Lilly with Buy Rating, Eyes Growth
Citi resumes Eli Lilly coverage with Buy rating, driven by optimistic tirzepatide forecasts for diabetes and obesity treatments.
- Latest
- Trending
Citi resumes Eli Lilly coverage with Buy rating, driven by optimistic tirzepatide forecasts for diabetes and obesity treatments.
Janet Rathod, with decades in cybersecurity, joins Johns Hopkins as CISO, enhancing security in education and health sectors.
AI drives sustainable computing by reducing energy use, even as demand grows.
Explore how U.S. states are leading AI regulation efforts, focusing on industry-specific and high-risk AI systems.
A security flaw in Apple's Vision Pro headset could infer data from gaze typing. It's patched in visionOS 1.3.
WebPT and Intel partner on AI motion capture for physical therapy, integrating RealSense technology into EMR for enhanced patient care.
The Virtual Reality market is set for rapid growth, expected to reach USD 143.86 billion by 2029, thanks to advancements ...
Discover how Bitcoin price fluctuations impact mining stocks. Is BTC the key to their success? On-chain analysis reveals insights.
Oil prices slump as global demand weakens, supply increases; BCA suggests reducing exposure amid bearish outlook.
Bitcoin miners sell $1.71B in 3 days. Can BTC maintain above $60,000 or is the rally fading?
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.